g discovery, development and
realization to measure the inputs and outputs of innovation during the
process of bringing new products to market. The six key innovations were
selected based on their impact on patient care and health outcomes:
targeted therapies with companion molecular diagnostics, monoclonal
antibodies (MAbs), stem cell therapy, RNA interference (RNAi), drug device
combinations and radiotherapy.
Additional benchmark findings based on data from the Deloitte report
-- Targeted therapies with companion molecular diagnostics - Have quickly
progressed from idea to realization as a number of new products entered
the market in the last few years. Discovery innovation remains active
and development continues.
-- Monoclonal antibodies - Have achieved widespread clinical acceptance in
the past three years after more than 20 years of variable progress.
However, the volume of discovery innovations has dropped off as they
move into the next stage, development. New structures and methods have
resulted in a fresh set of innovations, some of which are already in
-- Stem cells - Have achieved a high level of discovery innovation over
the past six years; however realization and development have not yet
-- RNAi - As a newer technology in the area of therapeutic treatment, RNAi
experienced discovery innovation only in the last four years; however,
there has been modest development and no realization yet.
-- Drug-device combinations - Have achieved general acceptance over the
past six years, and as this trend toward convergence evolves, a second
wave of innovation suggests future realization activity.
-- Radiotherapy - A relatively mature innovation, radiotherapy has
experienced a recent burst of innovation over the past three years
resultingPage: 1 2 3 4 5 Related biology technology :1
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20072
. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth3
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway4
. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%5
. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference6
. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum7
. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth8
. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 20079
. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference10
. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference11
. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference